The company said it leverages the clinical expertise of pharmacy teams to conduct custom savings reviews, with each patient’s medical and cost of its history in mind.
The FDA has given Viatris tentative approval for abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients.